Evidence map›Paper›PMID 32905614›Full record

ReviewInternational journal of dermatology2021

Keloids: a review of therapeutic management.

Samuel F Ekstein, Saranya P Wyles, Steven L Moran, Alexander Meves

Open access · greenAbstract readReview
In one paragraph

Review in International journal of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 6 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 6 syntheses or guidelines pooled it, 227 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. The role of IL-17 and Th17 cells in keloid pathogenesis.Archives of dermatological research · 2024
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Samuel F EksteinMayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN, USA.
Saranya P WylesDepartment of Dermatology, Mayo Clinic, Rochester, MN, USA.
Steven L MoranDivision of Plastic Surgery, Mayo Clinic, Rochester, MN, USA.
Alexander MevesDepartment of Dermatology, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0000-0001-7462-8288
Mayo Clinic in Arizona · US

Funding

Precision Medicine by Targeting Cell Adhesion in MelanomaK08CA215105 · NCI · MAYO CLINIC ROCHESTER · PI MEVES, ALEXANDER · 2017 to 2021
$854k
NCI NIH HHS CA215105NCI NIH HHS K08 CA215105
6 · The paper itself

Abstract

Keloid scar formation arises from a disorganized fibroproliferative collagen response that extends beyond the original wound margins because of excessive production of extracellular matrix (ECM). Despite treatment options for keloid scars including medical and surgical therapies, such as intralesional steroid injection and surgical excision, the recurrence rate remains high. Herein we consolidate recently published narrative reviews, systematic reviews, and meta-analyses to provide an overview of updated treatment recommendations for keloidal scar formation. PubMed search engine was used to access the MEDLINE database to investigate updates regarding keloid incidence and treatment. More than 100 articles were reviewed. Keloid management remains a multimodal approach. There continues to be no gold standard of treatment that provides a consistently low recurrence rate; however, the increasing number of available treatments and synergistic combinations of these treatments (i.e., laser-based devices in combination with intralesional steroids, or 5-fluorouracil (5-FU) in combination with steroid therapy) is showing favorable results. Future studies could target the efficacy of novel treatment modalities (i.e., autologous fat grafting or stem cell-based therapies) for keloid management. This review article provides updated treatment guidelines for keloids and discusses insight into management to assist patient-focused, evidence-based clinical decision making.

Indexed as

KeloidFluorouracilHumansInjections, IntralesionalRecurrenceSteroidsFluorouracilSteroids

Identifiers

PMID32905614
PMCPMC7940466
OpenAlexW3084386423

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.